The SYNCHRONIZE-1 Phase 3 trial of survodutide, a glucagon/GLP-1 dual agonist for obesity, has enrolled 725 participants across 14 countries with a mean BMI of 37.9 kg/m², with results expected after 76 weeks of treatment.
725 participants across 14 countriesPhase 3 SYNCHRONIZE-1 trial of survodutide, a novel glucagon/GLP-1 dual agonist, in adults with obesity (mean BMI 37.9) without diabetes — results pending after 76 weeks
What the researchers found
The SYNCHRONIZE-1 trial baseline characteristics (n=725 from 14 countries):
- Mean age: 47.1 years; 59.4% female
- Mean BMI: 37.9 kg/m²; mean waist circumference: 115.2 cm
- Geographic distribution: 47.3% North America, 21.0% Europe, 20.0% East Asia
- Obesity complications: hypertension (40.0%), dyslipidaemia (33.7%), prediabetes (30.2%)
- Mean HbA1c: 5.5%, eGFR: 93.0 mL/min/1.73 m², SBP/DBP: 127.0/82.7 mmHg
- Mean LDL cholesterol: 116.4 mg/dL; 21.8% on lipid-lowering drugs
Participants were randomized 1:1:1 to survodutide 3.6 mg, 6.0 mg, or placebo for 76 weeks. Primary endpoints are percent body weight change and achievement of ≥5% weight reduction at Week 76.
Why it matters
Survodutide represents a new approach to obesity treatment by combining GLP-1 and glucagon receptor activation. While GLP-1 drugs like semaglutide reduce appetite, glucagon receptor activation may additionally boost energy expenditure and fat burning. If successful, survodutide could offer even greater weight loss than current single-mechanism drugs.
How the study worked
This is a randomized, double-blind, placebo-controlled Phase 3 trial. Adults aged ≥18 with BMI ≥30 (or ≥27 with ≥1 obesity complication) without type 2 diabetes were enrolled across 14 countries. Participants were randomized 1:1:1 to weekly subcutaneous survodutide (up-titrated to 3.6 or 6.0 mg) or placebo for 76 weeks. This publication reports baseline characteristics only.
What this study cannot tell us
This publication reports only baseline characteristics — no efficacy or safety results are available yet. The trial excludes people with type 2 diabetes (a separate trial covers that population). The 76-week primary endpoint will provide important data, but longer-term outcomes and maintenance effects remain unknown. Comparison to other obesity drugs will require cross-trial interpretation since this is placebo-controlled.
How to read the evidence
This publication reports baseline characteristics of a well-designed Phase 3 RCT. No efficacy or safety results are yet available. The trial design (double-blind, placebo-controlled, multinational) is rigorous and will provide high-quality evidence once completed.
When this study was published
Published in 2026 with enrollment complete, this represents one of the newest obesity drug trials. Efficacy results from SYNCHRONIZE-1 are anticipated in the near future.
The bigger picture
The obesity drug landscape is rapidly expanding beyond GLP-1 monotherapy. Survodutide's dual glucagon/GLP-1 mechanism joins tirzepatide's GIP/GLP-1 approach and emerging triple agonists. Phase 2 data showed impressive weight loss, and this Phase 3 trial will determine whether survodutide can compete with or surpass existing treatments. The multinational enrollment across 14 countries reflects the global demand for effective obesity treatments.
Questions still open
- Will survodutide's dual mechanism produce greater weight loss than GLP-1-only drugs like semaglutide?
- Does glucagon receptor activation cause any unique safety concerns beyond those seen with GLP-1 drugs?
- How will survodutide compare to tirzepatide's GIP/GLP-1 dual mechanism in terms of efficacy and tolerability?
Common questions
How is survodutide different from semaglutide?
When will survodutide be available?
Read the original research
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
Diabetes, obesity & metabolism, 28(1), 337-346
Citation
le Roux, Carel W; Wharton, Sean; Bozkurt, Biykem; Platz, Elke; Bleckert, Gabriele; Ajaz Hussain, Samina; Brueckmann, Martina; Startseva, Elena; Kloer, Isabel M; Kaplan, Lee M. (2026). Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).. Diabetes, obesity & metabolism, 28(1), 337-346. https://doi.org/10.1111/dom.70196